Specific serum IgG at diagnosis of Staphylococcus aureus bloodstream invasion is correlated with disease progression

Journal of Proteomics

Volumn 128, Issue , 2015, Pages 1-7

  Stentzel, Sebastian ^a   Sundaramoorthy, Nandakumar ^a   Michalik, Stephan ^a   Nordengrün, Maria ^a   Schulz, Sarah ^a   Kolata, Julia ^a   Kloppot, Peggy ^b   Engelmann, Susanne ^b,c,d   Steil, Leif ^a   Hecker, Michael ^b   Schmidt, Frank ^a   Völker, Uwe ^a   Roghmann, Mary Claire ^e   Bröker, Barbara M ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Human; IgG; Protection; Serum antibodies; Staphylococcus aureus

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BACTERIAL IMMUNITY; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; LOW RISK PATIENT; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; BACTEREMIA; BLOOD; ISOLATION AND PURIFICATION; MICROBIOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

BACTEREMIA; BACTERIAL PROTEINS; BIOMARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84937153152     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.06.018     Document Type: Article

References (30)

1. Wertheim H.F.L., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. 2005, 5:751-762.
2. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
3. David M.Z., Daum R.S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010, 23:616-687.
4. Spellberg B., Daum R. Development of a vaccine against Staphylococcus aureus. Semin. Immunopathol. 2012, 34:335-348.
5. Fowler V.G., Allen K.B., Moreira E.D., Moustafa M., Isgro F., Boucher H.W., et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013, 309:1368-1378.
6. Verkaik N.J., de Vogel C.P., Boelens H.A., Grumann D., Hoogenboezem T., Vink C., et al. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 2009, 199:625-632.
7. Holtfreter S., Kolata J., Bröker B.M. Towards the immune proteome of Staphylococcus aureus - the anti-S. aureus antibody response. Int. J. Med. Microbiol. 2010, 300:176-192.
8. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001, 344:11-16.
9. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364:703-705.
10. Holtfreter S., Roschack K., Eichler P., Eske K., Holtfreter B., Kohler C., et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J. Infect. Dis. 2006, 193:1275-1278.
11. Cook M.C., Tangye S.G. Primary immune deficiencies affecting lymphocyte differentiation: lessons from the spectrum of resulting infections. Int. Immunol. 2009, 21:1003-1011.
12. Renner E.D., Rylaarsdam S., Anover-Sombke S., Rack A.L., Reichenbach J., Carey J.C., et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 2008, 122:181-187.
13. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
14. Cho J.S., Pietras E.M., Garcia N.C., Ramos R.I., Farzam D.M., Monroe H.R., et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 2010, 120:1762-1773.
15. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30:108-119.
16. Verkaik N.J., van Wamel W.J., van Belkum A. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 2011, 3:1063-1073.
17. Ohlsen K., Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int. J. Med. Microbiol. 2010, 300:402-410.
18. Kolata J., Bode L.G., Holtfreter S., Steil L., Kusch H., Holtfreter B., et al. Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non-carriers. Proteomics 2011, 11:3914-3927.
19. Adhikari R.P., Ajao A.O., Aman M.J., Karauzum H., Sarwar J., Lydecker A.D., et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J. Infect. Dis. 2012, 206:915-923.
20. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
21. Holtfreter S., Grumann D., Schmudde M., Nguyen H.T., Eichler P., Strommenger B., et al. Clonal distribution of superantigen genes in clinical Staphylococcus aureus isolates. J. Clin. Microbiol. 2007, 45:2669-2680.
22. Stentzel S., Vu H.C., Weyrich A.M., Jehmlich N., Schmidt F., Salazar M.G., et al. Altered immune proteome of Staphylococcus aureus under iron-restricted growth conditions. Proteomics 2014, 14:1857-1867.
23. Lindsay J.A., Moore C.E., Day N.P., Peacock S.J., Witney A.A., Stabler R.A., et al. Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes. J. Bacteriol. 2006, 188:669-676.
24. Grumann D., Nubel U., Broker B.M. Staphylococcus aureus toxins - their functions and genetics. Infect. Genet. Evol. 2014, 21:583-592.
25. Proctor R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 2012, 54:1179-1186.
26. van der Kooi-Pol M.M., de Vogel C.P., Westerhout-Pluister G.N., Veenstra-Kyuchukova Y.K., Duipmans J.C., Glasner C., et al. High anti-staphylococcal antibody titers in patients with epidermolysis bullosa relate to long-term colonization with alternating types of Staphylococcus aureus. J. Invest. Dermatol. 2013, 133:847-850.
27. Fritz S.A., Tiemann K.M., Hogan P.G., Epplin E.K., Rodriguez M., Al-Zubeidi D.N., et al. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin. Infect. Dis. 2013, 56:1554-1561.
28. Bröker B.M., Holtfreter S., Bekeredjian-Ding I. Immune control of Staphylocuccus aureus - regulation and counter-regulation of the adaptive immune response. Int. J. Med. Microbiol. 2014, 304:204-214.
29. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
30. McGeachy M.J., McSorley S.J. Microbial-induced Th17: superhero or supervillain?. J. Immunol. 2012, 189:3285-3291.